Cue Biopharma Analyst Ratings
Cue Biopharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/06/2023 | 201.89% | Piper Sandler | $7 → $8 | Maintains | Overweight |
| 06/26/2023 | 277.36% | Oppenheimer | → $10 | Assumes | Outperform → Outperform |
| 06/15/2023 | 201.89% | Stifel | → $8 | Reiterates | Buy → Buy |
| 05/15/2023 | 466.04% | JMP Securities | → $15 | Reiterates | Outperform → Outperform |
| 03/22/2023 | 201.89% | Stifel | $9 → $8 | Maintains | Buy |
| 03/22/2023 | 277.36% | Oppenheimer | → $10 | Reiterates | → Outperform |
| 11/21/2022 | 164.15% | Piper Sandler | → $7 | Initiates Coverage On | → Overweight |
| 08/24/2022 | 277.36% | Oppenheimer | $26 → $10 | Maintains | Outperform |
| 03/21/2022 | 881.13% | Oppenheimer | $32 → $26 | Maintains | Outperform |
| 03/18/2022 | 881.13% | Craig-Hallum | $28 → $26 | Maintains | Buy |
| 11/24/2020 | 1032.08% | Berenberg | → $30 | Initiates Coverage On | → Buy |
| 05/20/2020 | 1032.08% | Stifel | $25 → $30 | Maintains | Buy |
| 05/20/2020 | 1107.55% | Oppenheimer | $27 → $32 | Maintains | Outperform |
| 04/21/2020 | 843.4% | Stifel | $21 → $25 | Maintains | Buy |
| 04/09/2020 | 692.45% | Stifel | → $21 | Initiates Coverage On | → Buy |
| 03/06/2020 | 1032.08% | JMP Securities | $22 → $30 | Maintains | Outperform |
| 02/25/2020 | 918.87% | Oppenheimer | → $27 | Initiates Coverage On | → Outperform |
| 01/28/2020 | 881.13% | BTIG | → $26 | Initiates Coverage On | → Buy |
| 01/22/2020 | 730.19% | JMP Securities | → $22 | Initiates Coverage On | → Market Outperform |
| 07/26/2019 | 390.57% | Baird | → $13 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/06/2023 | 201.89% | 派珀·桑德勒 | 7 美元 → 8 美元 | 維護 | 超重 |
| 06/26/2023 | 277.36% | 奧本海默 | → 10 美元 | 假設 | 跑贏大盤 → 跑贏大盤 |
| 06/15/2023 | 201.89% | Stifel | → 8 美元 | 重申 | 購買 → 購買 |
| 05/15/2023 | 466.04% | JMP 證券 | → 15 美元 | 重申 | 跑贏大盤 → 跑贏大盤 |
| 03/22/2023 | 201.89% | Stifel | 9 美元 → 8 美元 | 維護 | 買 |
| 03/22/2023 | 277.36% | 奧本海默 | → 10 美元 | 重申 | → 跑贏大盤 |
| 11/21/2022 | 164.15% | 派珀·桑德勒 | → 7 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 2022 年 8 月 24 日 | 277.36% | 奧本海默 | 26 美元 → 10 美元 | 維護 | 跑贏大盤 |
| 03/21/2022 | 881.13% | 奧本海默 | 32 美元 → 26 美元 | 維護 | 跑贏大盤 |
| 03/18/2022 | 881.13% | Craig-Hallum | 28 美元 → 26 美元 | 維護 | 買 |
| 11/24/2020 | 1032.08% | 貝倫貝格 | → 30 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 05/20/2020 | 1032.08% | Stifel | 25 美元 → 30 美元 | 維護 | 買 |
| 05/20/2020 | 1107.55% | 奧本海默 | 27 美元 → 32 美元 | 維護 | 跑贏大盤 |
| 2020 年 4 月 21 日 | 843.4% | Stifel | 21 美元 → 25 美元 | 維護 | 買 |
| 2020 年 9 月 4 日 | 692.45% | Stifel | → 21 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 03/06/2020 | 1032.08% | JMP 證券 | 22 美元 → 30 美元 | 維護 | 跑贏大盤 |
| 2020 年 2 月 25 日 | 918.87% | 奧本海默 | → 27 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 01/28/2020 | 881.13% | BTIG | → 26 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 01/22/2020 | 730.19% | JMP 證券 | → 22 美元 | 啓動覆蓋範圍開啓 | → 市場跑贏大盤 |
| 07/26/2019 | 390.57% | 貝爾德 | → 13 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
What is the target price for Cue Biopharma (CUE)?
Cue Biopharma（CUE）的目標價格是多少？
The latest price target for Cue Biopharma (NASDAQ: CUE) was reported by Piper Sandler on November 6, 2023. The analyst firm set a price target for $8.00 expecting CUE to rise to within 12 months (a possible 201.89% upside). 7 analyst firms have reported ratings in the last year.
派珀·桑德勒於2023年11月6日公佈了Cue Biopharma（納斯達克股票代碼：CUE）的最新目標股價。該分析公司將目標股價定爲8.00美元，預計CUE將在12個月內升至12個月內（可能上漲201.89％）。去年有7家分析公司公佈了評級。
What is the most recent analyst rating for Cue Biopharma (CUE)?
Cue Biopharma（CUE）的最新分析師評級是多少？
The latest analyst rating for Cue Biopharma (NASDAQ: CUE) was provided by Piper Sandler, and Cue Biopharma maintained their overweight rating.
派珀·桑德勒對Cue Biopharma（納斯達克股票代碼：CUE）的最新分析師評級由派珀·桑德勒提供，Cue Biopharma維持增持評級。
When is the next analyst rating going to be posted or updated for Cue Biopharma (CUE)?
Cue Biopharma（CUE）的下一次分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cue Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cue Biopharma was filed on November 6, 2023 so you should expect the next rating to be made available sometime around November 6, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Cue Biopharma的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Cue Biopharma的最新評級是在2023年11月6日公佈的，因此您應該預計下一個評級將在2024年11月6日左右公佈。
Is the Analyst Rating Cue Biopharma (CUE) correct?
分析師對 Cue Biopharma（CUE）的評級是否正確？
While ratings are subjective and will change, the latest Cue Biopharma (CUE) rating was a maintained with a price target of $7.00 to $8.00. The current price Cue Biopharma (CUE) is trading at is $2.65, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Cue Biopharma（CUE）評級保持不變，目標股價爲7.00美元至8.00美元。Cue Biopharma（CUE）目前的交易價格爲2.65美元，超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。